Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer |
| terminated |
| Phase 1 / Phase 2 |
| 15 |
| Washington University School of MedicineOTHER |
| 1 |
| Jul 9, 2026 |
| clinicaltrials |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | terminated | Phase 1 | 21 | CelgeneINDUSTRY | 2 | Jul 9, 2026 | clinicaltrials |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | terminated | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma(HOLMBRAVE) | terminated | N/A | 10 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05891847 | Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | terminated | — | 150 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | terminated | Phase 1 | 47 | BeOne MedicinesINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | terminated | Phase 1 | 19 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities | terminated | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | terminated | Phase 1 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-3) | terminated | Phase 2 | 111 | GenmabINDUSTRY | 12 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 2 | Jun 30, 2026 | clinicaltrials |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | terminated | Phase 2 | 8 | Ranjana AdvaniOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04926324 | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | terminated | Phase 1 | 3 | University of IowaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05204290 | Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab | terminated | Early Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06191250 | --SuPERIOR Trial-- | terminated | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | terminated | N/A | 217 | University Hospital, LimogesOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03436745 | The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT05999968 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | terminated | Phase 1 | 10 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 26, 2026 | clinicaltrials |
| NCT03139058 | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck(fibr'HOM) | terminated | N/A | 2 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05207709 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype(HARMONIA) | terminated | Phase 3 | 61 | SOLTI Breast Cancer Research GroupOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | terminated | Phase 3 | 218 | Polaris GroupINDUSTRY | 3 | Jun 25, 2026 | clinicaltrials |
| NCT05716009 | Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML(GO-TAG) | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | terminated | Phase 3 | 107 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | terminated | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer(Neo-POLEM) | terminated | Phase 2 | 3 | University of SouthamptonOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | terminated | Phase 3 | 96 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | terminated | N/A | 57 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)(EPIDROP) | terminated | N/A | 100 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05350527 | Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery(SENEDOP) | terminated | N/A | 89 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07050836 | Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation | terminated | Early Phase 1 | 2 | University of Colorado, DenverOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00253318 | RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | terminated | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 30 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | terminated | N/A | 1 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2026source: clinicaltrials